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The Value of Screening for Amblyopia Revisited 
Jill Carlton and Carolyn Czoski-Murray 
Core Messages 
• Vision screening for children may be considered in terms of detection of 
amblyopia, strabismus and/or refractive error.  Variations exist within and between 
countries regarding vision screening for children in terms of programme content, 
referral criteria and personnel.  Recommendations state preschool vision screening 
programmes be conducted by orthoptists or by professionals trained and supported by 
orthoptists. 
• The justifications of vision screening for children include an increased risk of 
blindness to the healthy eye as result of injury of disease in adults with amblyopia.  
An increased risk of blindness is present as the non-amblyopic eye of an amblyope 
may become diseased or injured.   
• A recent report found that screening for amblyopia could not be considered as cost-
effective, but acknowledged that much uncertainty exists surrounding the short and 
long-term implications of the condition(s).  Further research is needed to provide such 
evidence. 
• Treatment of amblyopia associated with refractive error should incorporate a 
period of observation with glasses-wear alone to allow for “refractive adaptation” 
(also known as “optical treatment of amblyopia”).  Improvements in visual acuity can 
occur up to and beyond 20 weeks after glasses are prescribed.  Most improvement 
occurs in weeks 4 to 12.  In some cases further amblyopia therapy may not be 
required. 
• Children who undergo amblyopia therapy at an early age have been found to 
respond more quickly to occlusion than older children, and require less occlusion in 
total.  There is evidence to suggest that successful treatment of children aged over 7 
years can be achieved in cases of anisometropic, strabismic and mixed aetiology 
amblyopia. 
• Atropine has been found to be as effective as patching in the treatment of both 
moderate and severe amblyopia.   
• Recurrence of amblyopia may occur following treatment, with reported rates of 7% 
to 27%.  Factors influencing recurrence include age of the child at cessation of 
treatment, VA at the time of cessation of treatment and the type of amblyopia that is 
present.  
• Reported health related quality of life (HRQoL) implications of amblyopia include 
the impact of the condition upon stereoacuity; fine motor skills; reading speed; and 
interpersonal relationships.   
• The reported HRQoL implications of strabismus are related to physical appearance, 
particularly upon self-image and interpersonal relationships.  Surgical correction of 
strabismus has been reported to improve HRQoL. 
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Amblyopia 
Amblyopia is a sensory anomaly defined as defective unilateral or bilateral visual 
acuity (VA).  There are a number of classifications of amblyopia based on the 
aetiological cause(s).  The reported prevalence of amblyopia varies widely, from 1-
5%.  Differences in prevalence can be attributed due to the population studied (e.g. 
ethnicity), and whether the study sample was taken from a clinical cohort (where a 
greater prevalence would be expected) or a population-based study.  However, the 
most important factor which can account for differences in reported prevalence rates 
is that of amblyopia definition.  Over recent years a definition of amblyopia based 
upon a difference in VA of two or more Snellen or logMAR lines between eyes has 
been adopted.  However, there is no universally accepted definition of amblyopia in 
terms of VA deficit.  Studies that report upon amblyopia prevalence, diagnosis and/or 
treatment must be interpreted carefully, and often cannot be directly compared.  
Nonetheless, amblyopia is considered to be a common condition which occurs in 
childhood, and if left untreated will remain present throughout adult life.  This chapter 
will explore what is meant by screening; detection of amblyopia and strabismus 
through screening programmes; amblyopia treatment; and consequences of amblyopia 
and its treatment (both in the long and short-term). 
 
1.1  What is Screening? 
The purpose of screening is to identify persons as being at greater or lesser risk of 
developing, or having, a particular condition.  The United Kingdom (UK) National 
Screening Committee (NSC) defined screening as “a public health service in which 
members of a defined population, who do not necessarily perceive that they are at risk 
of, or are already affected by, a disease or its complications, are asked a question or 
offered a test to identify those individuals who are more likely to be helped than 
harmed by further tests or treatment to reduce the risk of a disease or its 
complications”1.  There are recognised criteria for screening relating to the condition 
itself; diagnosis; treatment and cost.  These are summarised in Table 1. 
 
1.1.2  Screening for amblyopia, strabismus and/or refractive errors 
Screening for amblyopia, strabismus and/or refractive errors has long been an emotive 
and contentious issue.  Differences in health care provision from one country to 
another can make it difficult to draw inferences on the possible benefits and risks 
associated with the implementation or withdrawal of such programmes.  For example, 
differences exist between the United Kingdom (UK) and the United States of America 
(USA).  Within the UK, vision screening of children was developed as part of the 
child health surveillance programmes established during the 1960’s and 1970’s.  The 
appropriateness of such programmes was called into question following a systematic 
review of their effectiveness2.  In 2003, the Health For All Children Report (also 
known as Hall 4) recommended changes in the way children are monitored and 
referred for suspected amblyopia and strabismus3, and the Child Health Promotion 
Programme (CHPP) recommended all children to be screened for visual impairment 
between four and five years of age by an orthoptist-led service4.  This 
recommendation has been adopted regionally in the UK, although not universally. 
 
Within the USA there is also widespread differences regarding preschool vision 
screening guidelines, policies and procedures.  Recommendations from the American 
Academy of Ophthalmology (AAO), American Association for Pediatric 
Ophthalmology and Strabismus (AAPOS) and the American Academy of Pediatrics 
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(AAP) are that vision screening should be performed on children between the ages of 
three and three and a half years of age5.  Despite the existence of such 
recommendations, current practice within the USA is totally non-standardised, with 
much variability by state and locality.  This was highlighted by Ciner et al6 who 
recommended that specific components of a preschool vision screening programme 
ought to be considered; including the tests to be conducted, parental education of the 
condition, and recording and referral criteria.   
 
Over recent years there has been a call to make any recommendations for vision 
screening for children more evidenced-based, and advances in the literature regarding 
screening test accuracy and treatment of amblyopia will only serve to facilitate this.  
However, the implementation of any recommendations is often driven by political 
rather than clinical factors. 
 
1.1.2.1  Screening for amblyopia 
The purpose of preschool vision screening for amblyopia is to detect children with 
unilateral or bilateral amblyopia.  Accurate detection of amblyopia is primarily 
achieved through VA testing.  The value of conducting other tests for the purpose of 
screening for amblyopia alone is minimal; some would argue additional tests could be 
included in the screening programme to detect amblyogenic factors (e.g. strabismus or 
refractive error). 
 
1.1.2.2  Screening for strabismus 
The purpose or value for preschool vision screening for strabismus alone could be 
questioned.  It may be argued that the detection of large, cosmetically apparent 
strabismus would be observed by parents or guardians and/or health care practitioners.  
Once noted, appropriate referral to an ophthalmologist would be initiated.  Therefore 
the justification of preschool vision screening for large-angled strabismus may not be 
valid.  The detection of small-angle strabismus however, is not as easy and requires 
expert testing from orthoptists and ophthalmologists.  The value of such detection 
remains under debate.  If the strabismus is so small that it is not cosmetically obvious, 
then it is unlikely that surgical treatment for the condition would be undertaken.  To 
that end, the value of screening may be questioned.  An argument for screening could 
be that the presence of a small-angle strabismus is an amblyogenic factor: amblyopia 
may not be present at the time of screening, however the existence of the strabismus 
would be suggestive that amblyopia is likely to develop within the critical period of 
vision development. 
 
1.1.2.3  Screening for refractive error 
Screening for refractive error alone is not commonplace.  The justification would be 
that the presence of significant refractive error may impact upon educational progress 
and daily living.  The existence of unequal refractive error (anisometropia) could be 
deemed an amblyogenic risk factor.  Indeed, the correction of any clinically 
significant refractive error during the critical period of vision development supports 
the notion of preschool vision screening.  
 
1.1.2.4  Screening for other ocular conditions 
Any form of preschool vision screening is likely to result in detection of other ocular 
conditions.  These may include ocular pathologies such as cataract or retinoblastoma; 
or may be related to motility, such as Duane’s or Brown’s syndrome.  Whilst such 
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conditions are of great clinical importance, not least because of their association with 
systemic health problems, the justification of screening for detection of these 
conditions alone cannot be justified.  To screen for such conditions in isolation is 
neither practical nor appropriate.  The economic benefit of adding such conditions to a 
screening programme for amblyopia and/or strabismus is negligible.  
 
1.1.3  Difference between a screening and diagnostic test 
There is difference between a screening test and a diagnostic test.  As the name 
implies, a screening test is used to identify and eliminate those with a given 
problem(s); there is no requirement for it to quantify the extent of any deficit or 
problem, or indeed for it to provide any information for diagnosis.  A diagnostic test 
provides information which can be used to help make a clinical diagnosis, and/or 
influence the management plan of the condition.  A diagnostic test often quantifies the 
extent or severity of the condition.  For example, photoscreening is used to detect 
refractive error (screening test); however the results would not be used to diagnose the 
extent of the refractive error present or indeed for the prescription of glasses.  This 
would be achieved through refraction (diagnostic test).   
 
1.1.4  Justification for screening for amblyopia and/or strabismus 
The justification of preschool vision screening for amblyopia and/or strabismus 
remains a controversial issue.  Referring to the NSC criteria of screening, the 
condition to be screened should be an important clinical condition.   The evidence 
relating to the condition’s importance and impact relate primarily to the consequence 
of amblyopia and/or strabismus in the short or long term.  It has been recognised that 
there is a detrimental effect of having reduced vision in one eye (as is the case with 
unilateral amblyopia).  Brown et al7 stated that in the presence of ocular disease, yet 
good VA in both eyes, subjects reported to have a higher health related quality of life 
(HRQoL) than those with good VA in only one eye. 
 
One of the arguments regarding the consequence of amblyopia refers to the risk of 
blindness to the healthy eye as a result of injury or disease.  Rahi et al8 reported upon 
the findings of the British Ophthalmological Surveillance Unit (BOSU), a national 
surveillance scheme for the study of rare ophthalmological disorders or events.  Over 
a two-year period the number of individuals with unilateral amblyopia with a newly 
acquired loss of vision in the non-amblyopic eye was recorded.  The authors were 
able to report upon the total population lifetime risk and annual rate of permanent 
visual impairment or blindness attributable to loss of vision in the non-amblyopic eye.  
In addition, the projected lifetime risk and annual rate of permanent visual impairment 
or blindness attributable to loss of vision in the non-amblyopic eye in individuals with 
amblyopia were reported.  It was found that the lifetime risk of visual impairment 
increased substantially from the ages 15-64 years and by 95 years of age (incidence 
per 100,000 total UK population, 5.67 [4.33-7.01 CI] compared to 32.98, [29.06-
36.89 CI]).  This can be attributed to the increased prevalence of other ocular 
disorders that occur with increasing age (such as cataract and age-related macular 
degeneration).  The authors stated that every year as a result of disease affecting the 
non-amblyopic eye, at least 185 people in the UK with unilateral amblyopia have 
vision loss to a level that is associated with detriment to quality of life.  It is possible 
that the incidence rates are greater than this, with only the minimum estimates of the 
risk of visual impairment after disease in the non-amblyopic eye being reported.  The 
authors stated that the lifetime risk of serious vision loss for an individual with 
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amblyopia was substantial and in the region of 1.2-3.3%.  This was supported by 
Chua and Mitchell9, who found that people with amblyopia had almost three times the 
risk of visual impairment in their better seeing eye compared to people without 
amblyopia. 
 
More recently, Van Leeuwen et al10 examined the excess risk of bilateral visual 
impairment among individuals with amblyopia as part of the Rotterdam study (a 
population-based prospective cohort study of the frequency and determinants of 
common cardiovascular, locomotor, neurological and ophthalmological diseases).  
They found that the estimated lifetime risk of bilateral visual impairment is almost 
doubled in those who also have a diagnosis of amblyopia.  The authors reported that 
the number of individuals needed to treat to prevent one case of binocular visual 
impairment is 12.5.   
 
When vision loss in the non-amblyopic eye in the presence of amblyopia does occur 
(through injury or disease), the effect upon the individual is often devastating.  There 
have been reported cases of plasticity in the visual system, even in adulthood, 
whereby improvements in VA in the amblyopic eye have been observed11.    
 
Another argument for the notion of preschool vision screening for amblyopia and/or 
strabismus is the impact of having either condition upon quality of life.  This will be 
examined in more detail towards the end of the chapter. 
 
1.1.5  Recent reports examining preschool vision screening 
The scarcity of evidence which would allow decision makers in the UK NHS to fund 
screening programmes with confidence that it is an efficient use of limited health care 
resources has made screening for amblyopia problematic.  To be cost effective a 
programme has to demonstrate that it is first clinically effective.  Issues of how 
disinvestment in existing technologies or health care programmes is carried out is 
becoming increasingly important in the UK health care setting, as new evidence based 
technologies are mandated by the National Institute for Health and Clinical 
Excellence (NICE).  Decisions concerning which programmes can be continue to be 
funded from the health care budgets which are under increasing pressure due to the 
mandated programmes from NICE are being made in local areas.  The problems 
associated with older established programmes relate mainly to the reality that often 
these were implemented many years ago when evidence was limited, or they were 
never subject to the level of scrutiny that is currently expected for any new technology 
or programme.  The recent review of screening for amblyopia is one such area.  
 
In 2008, the Health Technology Assessment report on preschool vision screening was 
updated, examining both the clinical and cost-effectiveness of screening programmes 
for amblyopia and strabismus in children up to the ages of four to five years12.   
A systematic review of the literature examining the clinical and cost effectiveness of 
screening children for amblyopia and strabismus before the age of five years was 
undertaken.  Cost effectiveness and expected value of perfect information (EVPI) 
modelling was reported.  EVPI modelling is used in cost-effectiveness analysis to 
attempt to establish the benefits of undertaking research which would reduce the costs 
of uncertainty. The cost of uncertainty in this case is that the wrong disinvestment 
decision could be made.  
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Following a review of the literature a natural history model was constructed, which 
described the incidence and progression of amblyopia to age 7 years.  As is customary 
a separate model which extrapolated the costs and effects of amblyopia over an 
individual’s remaining lifetime was also constructed.  These models were 
incorporated into a separate screening model which represented the potential impact 
of treatment.  The expected health outcome for the individual was defined as the 
expected number of cases remaining in a population of 7 year olds.  That is those 
children for whom treatment was either unsuccessful or who had failed to be detected.  
 
A post-screening model was constructed to estimate the long term effects of 
childhood amblyopia on a cohort of individuals who would have bilateral or unilateral 
vision loss over a 93 year time horizon.  The costs associated with the screening 
programme and the benefits (expressed as utility weights) were applied to both vision 
loss across the model’s time horizon allowed us to give the estimated costs and 
consequences of amblyopia.  
 
The model population was informed by the literature reviews.  It was identified during 
the data extraction process that there was a significant lack of quantitative data 
available which could be used in the model.  This problem was addressed by having a 
pragmatic approach to estimate the transitions in the model for which amblyogenic 
factors translated into a number of visual acuity states.  A number of experts who 
were able to confirm or reject the plausibility of the assumptions that were made were 
consulted.  It was not possible to use any empirical data which could have informed 
the effectiveness of treatment for amblyogenic factors.  It was assumed that by 
removing the risk factor for refractive error the outcome would be 100% effective. 
Strabismus treatment is acknowledged to be less successful therefore the outcomes for 
removing the amblyogenic risk was considered to be between 0 and 30%.  
 
Carlton et al12 reported that the available evidence did not support the screening 
programme for amblyopia and amblyogenic factors.  Economic evaluation showed 
that screening for amblyopia and strabismus in children could not be considered as a 
cost-effective use of resources.  Analysis of the cost effectiveness using the available 
research data found that screening was not cost-effectiveness at currently accepted 
quality adjusted life years (QALY) values.  (QALYs are used in cost-utility studies, 
and consider both the duration of health states and their impact on HRQoL13).   
However, the lack of evidence highlighted a need for further research into the impact 
of amblyopia and amblyogenic factors in the long-term.  The lack of evidence 
surrounding the long term impact of amblyopia increased the level of uncertainty in 
the model.  By making a number of assumptions on utility loss (that is, the impact 
upon quality of life) the model demonstrated that screening could become highly cost 
effective.  EVPI modelling showed that the value of eliminating uncertainty ranges 
between £17,000 to over £100,000 per QALY.  That is, the impact of amblyopia upon 
a person’s quality of life (in the short or long-term) is still unknown, and guesstimates 
of such impact lead only to more uncertainty. 
 
These findings may not provide the ideal result for decision makers as the answers are 
not clear cut.  Cost-effectiveness alone should not be the deciding factor in the 
provision of preschool vision screening.  For example, the issue of equity may also 
need to be considered.  This is particularly relevant in communities where there may 
be a greater prevalence of amblyopia or strabismus which are failed to be detected or 
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acted upon by parental observation alone.  The figures reported above linking the cost 
per QALY are those which are applied to new technologies.  The QALY threshold for 
disinvestment is undefined at present.  
 
The German Institute for Quality and Efficiency in Healthcare (IQWIG) is an 
independent scientific institute that investigates the benefits and harms of medical 
interventions.  In producing reports upon the assessment of an intervention (such as 
screening) IQWIG adhere to strict inclusion and exclusion criteria in the reviewing of 
existing literature surrounding the given subject.  In 2008, IQWIG assessed the 
benefits of screening for visual impairment in children up to the age of 6 years14.  
They concluded that “no robust conclusions” could be directly inferred from the 
studies identified in their review.  To that end, the notion of preschool vision 
screening could neither be supported nor rejected. 
 
Summary for the clinician 
• The purpose of screening is to identify persons as being at greater or lesser risk of 
developing, or having, a particular condition.  Screening should be considered in 
terms of the condition, diagnosis, treatment and the screening programme itself. 
• Vision screening for children may be considered in terms of detection of 
amblyopia, strabismus and/or refractive error.  Variations exist within and between 
countries regarding vision screening for children in terms of programme content, 
referral criteria and personnel.   
• The justifications of vision screening for children include an increased risk of 
blindness to the healthy eye as result of injury of disease in adults with amblyopia.   
• An increased risk of blindness is present as the non-amblyopic eye of an amblyope 
may become diseased or injured.   
• Recent reports indicate that further evidence is required to support the notion of 
preschool vision screening despite seminal research examining diagnosis, treatment 
and consequence of amblyopia, strabismus and/or refractive error.
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1.2  Screening tests for amblyopia, strabismus and/or refractive error 
The accurate detection of amblyopia, strabismus and/or refractive error undoubtedly 
forms a critical factor in the reported success of any preschool vision screening 
programme.  However, much variation exists both within and between countries as to 
the content of vision screening programmes.  This includes the age at which the child 
is screened; referral criteria of the screening programme; and indeed the personnel 
administering the tests that form the screening programme.  Due to such differences it 
is often difficult to make direct comparisons between studies which report upon vision 
screening success.  Much has been contributed to the literature over recent years, 
largely through the work of the Vision in Preschoolers Study (VIP). VIP is a multi-
centre study, conducted in the USA, whose purpose is to evaluate whether there are 
tests, or combinations of tests, that can be used effectively in preschool vision testing.   
 
The effectiveness of a screening test in detecting a condition is considered in terms of 
sensitivity, specificity and positive and negative predictive values.  Sensitivity is 
defined as the proportion of individuals with the target condition in a population who 
are correctly identified by a screening test.  Specificity is the proportion of individuals 
free of the target condition in a population who are correctly identified by a screening 
test.  Positive predictive values describe the proportion of individuals with a positive 
result who have a target condition; and negative predictive value is the proportion of 
individuals who test negative who do not have a target condition. 
 
1.2.1  Vision tests 
The use of crowded logMAR acuity is the gold-standard VA measure in adults both 
within clinical and research settings.  This is also becoming the case with VA 
measurement in children.  Steps have been made to identify normative values of 
paediatric VA using different vision tests, protocols of testing, and repeatability of 
testing 15-19.  The preference as to which vision test that is to be included in a 
screening programme is not always clear.  Often a number of vision tests may be 
included within the one screening programme to incorporate factors such as a child’s 
comprehension and ability to perform a test.  It is outside the scope of this chapter to 
report upon the relative sensitivity and specificity of each vision test.  However, it 
should be noted that the cut-off points used for referral within a screening programme 
should be directly related to the specific vision tests used within that screening 
programme.  That is, it should not be generic, with an arbitrary referral point (such as 
0.2 logMAR or worse).  A VA level that is achieved using one vision test may be 
different to that achieved using an alternative vision test.  The referral criteria should 
be stipulated for each vision test that could be used within the screening programme. 
 
1.2.2  Cover-uncover test 
The cover-uncover test is used to detect the presence of strabismus, and is deemed to 
be the gold standard for detecting strabismus.  However there are few studies which 
report upon the sensitivity and specificity of the test itself.  Williams et al20 were able 
to report the sensitivity and specificity of the cover-uncover test on children who had 
been screened at the ages of 8, 12, 18, 25, 31 and 37 months.  At 37 months, the 
sensitivity of the test was calculated to be 75% (95% CI, 0.577 to 0.899%), with a 
specificity of 100%. 
 
The VIP study also assessed the effectiveness of the cover-uncover test in detecting 
strabismus, amblyopia, reduced VA and refractive error21.  The results are 
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summarised in Table 2.  The results of this study indicated that the cover-uncover test 
is more sensitive at detecting the presence of strabismus compared to detecting the 
presence of amblyopia, refractive error or reduced VA. 
 
1.2.3  Stereoacuity 
The inclusion of stereoacuity tests within preschool vision screening programmes 
could be considered as a contentious issue.  VIP22 stated that most guidelines 
recommend a test of stereopsis.  However, if a child was found to have normal VA, 
no strabismus, and no clinically significant refractive error yet failed to demonstrate 
adequate evidence of stereoacuity, should they be referred for further investigation?  
A number of stereotests are available for use as part of a preschool vision screening 
programme, however normative paediatric values of stereopsis have not been 
identified for some of these tests.  In the absence of such data the appropriateness of 
inclusion of such tests could be questioned.  Stereotests which involve a pass/fail 
response could be deemed as more appropriate for the purpose of screening for vision 
problems. 
 
The VIP has reported upon the testability of two different stereotests used to screen 
for vision disorders, the Random Dot E and the Stereo Smile test21;23.  The results 
reported by condition type are summarised in Table 3.  The results indicated that both 
stereotests are more accurate at detecting the presence of amblyopia and strabismus 
compared to that of reduced VA or refractive error.   
 
In a further study, VIP examined the sensitivity of the same stereotests when the 
specificity was set at 0.94.  The results are summarised in Table 4, and show that the 
Stereo Smile test was more accurate than the Random Dot E in detecting most target 
conditions of screening. 
 
1.2.4  Photoscreening and/or autorefraction 
The use of photoscreeners and/or autorefractors in preschool vision screening is 
extremely varied.  Within the USA they are commonplace, and the variety of different 
makes and models make summarising literature extremely difficult.  The use of such 
instruments within UK preschool vision screening programmes is much less frequent.  
When considering the appropriateness of photoscreeners and/or autorefractors in 
preschool vision screening it is important to recognise their accuracy when compared 
to a gold-standard (usually a refraction performed under full cycloplegia).  There are 
notable advantages and disadvantages of photoscreening when compared to 
autorefraction.  One of the main differences is that of cost.  After the initial expense of 
purchase, there is minimal additional cost to autorefraction.  Photoscreening however 
requires printing of the image, and depending upon who is administering the test, 
interpretation of the results.  The implications of both these factors lead to a higher 
overall expense when incorporated into a vision screening programme. 
 
It should also be noted that the primary aim of the use of a photoscreener or 
autorefractor is the detection of refractive error.  That is, it may detect an amblyogenic 
factor, but not amblyopia itself.  Similarly, the presence of strabismus may also be 
detected, although understandably the sensitivity and specificity rates of these are 
considerably lower than those of detecting refractive error. 
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It is beyond the scope of this chapter to review and appraise literature describing 
specific photorefractors and/or autorefractors.  Important points to note when 
considering such articles include; the study population (including age, ethnicity and 
whether general or clinical); test setting (e.g. environment); sensitivity and specificity 
of the test; the personnel conducting the test; and whether any comparison is made to 
the gold standard (in this case full refraction under cycloplegia).   
 
1.2.5  What to do with those who are unable to perform screening tests? 
Successful testing of children is largely dependent upon the child’s cooperation and 
compliance.  The decision about whether to refer those children who are unable to 
perform screening tests is difficult.  Some would argue that such children ought to be 
referred for further investigation, for the reason that they are unable to perform the 
screening tests due to the presence of an ocular condition.  Others would say that this 
may not be the case, and that cooperation may be the true issue.  The prevalence of 
ocular conditions amongst children who were unable to perform preschool screening 
tests has been investigated and it was found that preschool children who were unable 
to perform the screening test were at a higher risk of higher amblyopia, strabismus, 
significant refractive error, or unexplained low VA compared to children who had 
passed the screening test24.  This led the authors to recommend that these children 
ought to be referred or retested at a later date possibly with a different test.  The 
impact of recall and re-testing, or automatic referral will undoubtedly affect the 
overall clinical and cost-effectiveness of any preschool vision programme. 
 
1.2.6  Who should administer the screening programme? 
Within the UK it is recommended that preschool vision screening programmes be 
conducted by orthoptists or by professionals trained and supported by orthoptists3;4.  
In the USA preschool vision screening is usually conducted by nurses and lay people.  
The use of lay people to administer screening tests does have advantages, particularly 
when considering the economic burden of a screening programme.  Lay screeners are 
a cheaper alternative to eye care professionals, such as orthoptists, optometrists or 
ophthalmologists.   
 
Concerns regarding training and assessment of lay screeners have been raised; are lay 
screeners as accurate as eye care professionals in detecting amblyopia, strabismus 
and/or refractive error?  This question was addressed by VIP, who assessed the 
performance of lay screeners in administering preschool vision screening tests 
compared to nurse screeners25.  In this study, the screening tests conducted included 
assessment of refractive error, VA, and stereoacuity.  Two hand-held autorefractors 
were used to detect the presence of refractive error.  VA was assessed at two different 
testing distances; a linear test was performed at 10ft, and a single, crowded test 
administered at 5ft.  The results of the study demonstrated that although nurse 
screeners appeared to slightly higher sensitivities in the assessment of refractive error 
and presence of stereoacuity compared to lay screeners, the differences were not 
statistically significant.   
 
However when examining the results of VA testing, the authors reported that nurse 
screeners achieved significantly higher sensitivity than lay screeners with the linear 
VA test.  Whilst the authors make no recommendations for future screening protocol 
strategies, their results could be interpreted in two ways.  The lack of statistically 
significant differences in detection of refractive error or stereoacuity with tests 
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administered by lay screeners could support the use of such personnel in vision 
screening programmes.  However, the differences observed in VA testing between lay 
screeners and nurse screeners could suggest that nurse screeners would be more 
effective in detecting vision anomalies.  Differences in screening programmes 
between countries will undoubtedly continue to exist, however recommendations as to 
who should conduct screening based upon personnel costs alone may not be 
appropriate. 
 
Summary for the Clinician 
• Content of vision screening programmes vary widely.  Most involve assessment of 
visual acuity for which a large number of tests are available.  The gold standard is a 
crowded logMAR based test.  Referral criteria should be specific for the test used. 
• The use of photoscreeners and/or autorefractors in vision screening programmes is 
not universal.  The use of photoscreeners and/or autorefractors will have an impact 
upon the cost-effectiveness of screening.  
• The inclusion of stereotests in preschool vision screening programmes could be 
questioned.   
• Recommendations state preschool vision screening programmes be conducted by 
orthoptists or by professionals trained and supported by orthoptists.
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1.3  Treatment of amblyopia 
The clinical management of amblyopia is determined following careful consideration 
on a case-per-case basis, taking into account a number of factors including the type of 
amblyopia present; the patient’s age; and the level of VA in the amblyopic eye.  
Nonetheless, advances in evidence-based medicine have led to a number of 
recognised studies which have reinforced or altered clinical practice in the 
management of this condition.  The Pediatric Eye Disease Investigator Group 
(PEDIG), based in the USA, is a multi-centre group dedicated to clinical research in 
strabismus, amblyopia and other eye disorders affecting children.  Funded by the 
National Eye Institute (NEI), this group have investigated many aspects of the clinical 
course of amblyopia and its treatment.  The Monitored Occlusion Treatment of 
Amblyopia Study Cooperative (MOTAS Cooperative) is a multidisciplinary group of 
ophthalmologists, orthoptists, basic scientists and statisticians dedicated to 
investigating amblyopia treatment.  Based in London (UK), it is funded by the 
charities Guide Dogs for the Blind Association, and Fight for Sight.  They have 
conducted two clinical trials to identify the response of amblyopia to occlusion 
therapy.   Data from both the studies conducted by PEDIG and the MOTAS 
Cooperative have contributed to our understanding of the management of amblyopia.   
 
1.3.1  Type of treatment 
Amblyopia is treated by obscuring the image from the good eye to promote use of the 
amblyopic eye.  This can be achieved through occlusion treatment (patching or 
pharmacological occlusion, in the form of atropine); or through optical penalisation.  
There are notable advantages and disadvantages to different treatment modalities in 
terms of compliance, ease of administration and visual acuity outcome.  Comparison 
of studies investigating the effectiveness of treatment of amblyopia is hindered, due to 
differing definitions of both “amblyopia” and “treatment success”.  In addition, 
clinicians have long recognised that the amount of treatment prescribed and the 
amount of treatment actually undertaken may differ.  Objective measurement of the 
amount of occlusion worn has been made possible with the introduction of occlusion 
dose monitors (ODM).  ODMs were developed and validated by the Monitored 
Occlusion Treatment for Amblyopia Study (MOTAS) Cooperative (UK), and since 
then have been used to examine whether there is a dose-response to occlusion therapy. 
 
1.3.2  Refractive adaptation 
One of the main concepts that has arisen over the recent years in amblyopia treatment 
is that of refractive adaptation (or “optical treatment of amblyopia” as it is sometimes 
known26).  There has been increasing evidence to suggest that the treatment of 
amblyopia in the presence of refractive error should incorporate observation of VA 
following the prescription of glasses alone26-29.  These studies report increases in VA 
in subjects such that some did not require any additional treatment for their amblyopia.  
Prior to such studies, it was uncertain whether observed improvements in VA 
achieved were as a result of amblyopia therapy (i.e. occlusion) or due to glasses-wear 
alone. 
   
It is becoming increasingly clear that refractive adaptation is a recognised period in 
amblyopia therapy.  The time taken to reach this period however remains under 
debate.  The MOTAS studies utilised a period of 18-weeks observation27-29; however 
the PEDIG reported 83% of their study group demonstrated stability of improvement 
in VA before 15 weeks, however one patient improved for 30 weeks26.  Improvements 
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in VA have been described to occur after 20 weeks, but not considerably, with the 
majority of improvement having occurred in weeks 4 to 1230.   
 
One of the arguments supporting the notion of vision screening is the detection of 
bilateral refractive error.  Wallace et al31, as part of the PEDIG study, examined the 
improvements in VA in children with bilateral refractive amblyopia aged between 3 
and 10 years.  They reported that correction of refractive error improved VA, with 
only 12% of the cohort requiring additional amblyopia therapy in the form of 
occlusion or atropine.   
 
1.3.3  Conventional occlusion 
Patching treatment is often initiated as the first-line approach in amblyopia therapy.  
One advantage of patching treatment is that the effects are reversible; in that once the 
patch is removed the non-amblyopic eye is favoured, which is not the case with 
pharmacological occlusion.  Since the acknowledgement of refractive adaptation it 
has been necessary to confirm that occlusion therapy is also effective in the 
management of amblyopia.  PEDIG compared the effect of daily patching versus a 
control group of amblyopes in children aged 3 to 7 years, following a period of 
refractive adaptation.  An improvement in VA was observed in both groups after 5-
weeks, and as expected a greater improvement reported in the patched group32.    
 
The MOTAS Cooperative have investigated the amount of occlusion required to 
improve VA and explore the dose-response relationship in amblyopia therapy28.  They 
found that most children required between 150-250 hours of occlusion, irrespective of 
the type of amblyopia present.  Specific characteristics were observed to affect the 
response, such as the age of the patient; where older children required a greater 
amount of occlusion to achieve similar gains in VA compared to their younger 
counterparts.  Younger children have been observed to respond more quickly and with 
less occlusion than older children; however the final level of VA achieved is similar 
for all ages29.   
 
Traditionally clinicians have recommended near visual activities whilst occlusion 
therapy is undertaken, however there has been little research to justify such advice.  
The PEDIG investigated whether performing such activities influenced the 
improvement in VA outcome when treating amblyopia in conjunction with occlusion 
therapy33.  No statistical evidence to support the notion that near visual activities 
improved VA outcome in their study group was found.  It should be noted that the 
study group were prescribed only 2 hours of patching per day, and that the authors 
make no inference as to whether the results would be similar in subjects patched for a 
greater or lesser time. 
 
1.3.4  Pharmacological occlusion 
Pharmacological occlusion (i.e. atropine) has notable benefits; it could be argued that 
it carries with it less of a social stigma compared to the wearing of an eye patch.  One 
disadvantage of pharmacological occlusion is that the effects are not readily reversible; 
it can take several weeks for the effects of atropine to wear off.  Concerns also exist 
regarding its efficacy as a treatment modality, with some clinicians believing it to be a 
less effective treatment when compared to conventional occlusion.  Studies conducted 
by PEDIG examined the effectiveness of conventional occlusion versus 
pharmacological occlusion in the treatment of moderate amblyopia (20/40 to 20/80)34 
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and severe amblyopia (20/100 to 20/400)35.  Either treatment modality was found to 
be appropriate with similar improvements in VA in either group.  The decision 
towards which therapy should be adopted may now be based on other factors.  One 
such factor may be the instillation of the atropine itself.  The effect of different 
atropine regimens in the treatment of moderate amblyopia (20/40 to 20/80) was 
investigated.  Comparisons were made between the observed effect of daily atropine 
instillation to that of weekend-only atropine instillation36.  Both groups were observed 
to show improvements in VA of similar magnitudes.  It could be argued that the need 
for daily atropine instillation is redundant, thereby improving the therapeutic 
experience for the child.  This in itself may encourage parents and/or clinicians to 
adopt this treatment modality. 
 
1.3.5  Optical penalisation 
Another treatment option in the management of amblyopia is that of optical 
penalisation.  This is where lenses are used to induce a defocused image of the non-
amblyopic eye.  Tejedor and Ogallar37 directly compared the effects of atropine 
versus optical penalisation in the treatment of mild to moderate amblyopia (VA of at 
least 20/60).  This small study found greater improvements in VA in the atropine 
group after six months of therapy, which may be attributed to the child peeking over 
or around the glasses and thereby not achieving the desired affect of the optical 
penalisation.  Although optical penalisation remains a useful treatment option in 
specific clinical situations, it is often not considered an appropriate first-line choice of 
therapy in the management of amblyopia. 
 
1.3.6  Effective treatment of amblyopia in older children (over the age of 7 years) 
There has been strong evidence that treatment for amblyopia is more effective prior to 
the age of 7 years.  Despite this, amblyopia therapy has been reported to be successful 
in older children with either anisometropic38-42 and/or strabismic amblyopia40-42.  
Treatment of strabismic amblyopia in the older child should be pursued with caution, 
as there is a notable risk of reducing the density of suppression, and thereby inducing 
intractable diplopia in these patients.  A number of studies which reported upon 
improvements in VA in older children with strabismic or mixed aetiology amblyopia 
following treatment do not report whether the density of suppression had been 
measured, or if any other side-effects had been observed40-42.  Despite there being 
some evidence to suggest that successful treatment of amblyopia in the older child is 
possible, earlier intervention is more advantageous, and to that end supports the 
notion of preschool vision screening. 
 
1.3.7  Treatment compliance 
The successful management of amblyopia is intrinsically linked to treatment 
compliance and adherence to therapy.  This in itself is multi-factorial in nature.  The 
development and application of ODMs has meant that reasons for non-compliance 
can be more thoroughly investigated.  In particular, ODMs have highlighted the 
discrepancy between the amount of occlusion prescribed and the amount administered.  
Clinicians have long recognised that the amount of occlusion carried out often falls 
short of their recommended treatment plan.  Stewart et al29 reported upon the effect of 
six hours a day occlusion compared to 12 hours a day occlusion in the treatment of 
strabismic and/or anisometropia amblyopia.  They found that the amount of occlusion 
received was 66% and 50% of their prescribed six and 12 hours a day, respectively.  
Such information ought to be taken into account when prescribing occlusion therapy 
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Loudon et al43 examined some of the limiting factors of occlusion therapy for 
amblyopia and reported parental fluency in the national language and level of 
education were both predictors of low compliance.  Parental understanding of the 
condition and treatment has also been reported as being an important factor in the 
successful management of amblyopia.   
 
Adherence to treatment must be considered not only in terms of the child complying 
with therapy, but in the parent/guardian administering the treatment as advocated by 
the ophthalmologist and/or orthoptist.  Searle et al44 found two variables that were 
significant predictors of compliance with occlusion therapy.  They reported that self-
efficacy (the belief in the ability to patch their child) was positively associated with 
treatment compliance.   The parental belief that occlusion therapy prohibits the child’s 
activities was negatively associated with treatment compliance. 
 
1.3.8  Other treatment options for amblyopia 
The use of photorefractive keratectomy (PRK) for the treatment of anisometropia in 
children has not been fully investigated and concerns exist surrounding the long-term 
response to refractive surgery in terms of VA and corneal status.   However, it could 
be postulated that if the amblyopic risk factor of high anisometropia is removed early 
then the possibility of development of dense amblyopia would be reduced.  Paysse et 
al45 reported the results of a small study of children with high anisometropia, and 
found improvements in both VA and stereopsis following treatment.  However, 
compliance with amblyopia therapy remained unaffected in this study group 
following treatment.  The use of refractive surgery in children is not commonplace 
and there remains a need for a large randomised clinical trial to fully investigate the 
possible benefits of this form of treatment.   
 
1.3.9  Recurrence of amblyopia following therapy 
Recurrence of amblyopia has been observed in patients following the cessation of 
treatment, with rates varying widely.  Some recent studies have sought to identify 
factors which may influence whether recurrence is likely to occur46-49.  These include; 
age of termination of treatment; VA at the time of cessation of treatment; and which 
type of amblyopia is present.  Recurrence in amblyopia was noted in 7% to 27%, with 
a low reported recurrence in children who underwent treatment after the age of 7 
years49.  Age of the child at the cessation of treatment does appear to be a factor, with 
recurrence inversely correlated with patient age46. 
 
Summary for the Clinician 
• Treatment of amblyopia associated with refractive error should incorporate a 
period of observation with glasses-wear alone to allow for “refractive adaptation” or 
“optical treatment of amblyopia”.  Improvements in VA can occur up to and beyond 
20 weeks after glasses are prescribed, but most improvement occurs in weeks 4 to 12.  
In some cases further amblyopia therapy may not be required. 
• There is evidence to suggest that children who undergo amblyopia therapy at an 
early age respond more quickly to occlusion than older children, and require less 
occlusion in total. 
• Pharmacological occlusion, in the form of atropine, has been found to be as 
effective as conventional occlusion (patching) in the treatment of both moderate and 
severe amblyopia.  Weekend-only atropine instillation has been shown to produce 
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similar improvements in VA as daily atropine instillation in the treatment of moderate 
amblyopia. 
• There is evidence to suggest that successful treatment of children aged over 7 years 
can be achieved in cases of anisometropic, strabismic and mixed aetiology amblyopia. 
• The development of ODM has informed not only the occlusion-dose response of 
amblyopia treatment, but also reasons for poor treatment compliance.  Parental 
understanding of the condition and belief in therapy may influence treatment outcome. 
• Recurrence of amblyopia may occur following treatment, with reported rates of 7% 
to 27%.  Factors influencing recurrence include age of the child at cessation of 
treatment, VA at the time of cessation of treatment and which type of amblyopia is 
present.  
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1.4  Quality of life 
When considering the application of any screening programme, thought should be 
made regarding the impact of testing for the target condition; the impact the target 
condition has upon a person; and the impact subsequent treatment of that target 
condition may have upon a person.  One of the ways in which the health impact of a 
disease or condition can be assessed is through measures of quality of life, or health-
related quality of life (HRQoL).  Over recent years there has been a growing body of 
evidence which has examined the impact of amblyopia and/or strabismus upon a 
person’s physical and emotional well-being.   
 
1.4.1  The impact of amblyopia upon HRQoL 
There have been a number of studies which have investigated the impact of 
amblyopia upon HRQoL.  These have examined the effect of amblyopia upon 
stereoacuity and motor skills50;51; reading speed ability52; educational attainment9; and 
emotional well-being44;53-58. 
 
1.4.2  Stereoacuity and motor skills in children with amblyopia 
Stereoacuity and motor skills have been reported to be impaired in children with 
amblyopia.  Webber et al50 investigated the functional impact of amblyopia in 
children by assessing the fine motor skills of those with amblyopia compared to age-
matched control subjects.  It was noted that the subjects with amblyopia performed 
significantly poorer in most of the fine motor skills tests conducted as part of the 
study, particularly in the tasks related to time.  The results were even more noticeable 
in those children with a diagnosis of amblyopia and strabismus.  Hrisos et al51 
investigated the influence of VA and stereoacuity on the performance of preschool 
children undertaking tasks that required visuomotor skills and visuospatial ability.  
The authors reported that reduced monocular VA itself did not relate to any ability of 
task performance, but stereoacuity was found to affect task performance, with 
subjects with reduced steroacuity noted to have poorer responses to 
neurodevelopment tasks.  Such studies support the notion that amblyopia is associated 
with negative implications to HRQoL. 
 
1.4.3  Reading speed and reading ability in children with amblyopia 
Reading speed and reading ability has been assessed in children with amblyopia.  
Stifter et al52 reported that maximum reading speed was significantly reduced in those 
with the condition.  Therefore they could be deemed to have a functional reading 
impairment when compared to normal sighted controls.  It is recognised that reading 
ability is multifactorial in nature, and is influenced by comprehension.  The study 
does not imply that children with unilateral amblyopia are poor readers under 
binocular conditions, for the binocular VA and reading acuity of the two groups were 
comparable. 
 
1.4.4  Impact of amblyopia upon education 
Chua and Mitchell9, as part of the Blue Mountains Eye Study in Australia (a 
population based survey of people aged 49 years or older), examined the 
consequences of amblyopia on education, occupation and long term vision loss.  In 
their study population, the presence of amblyopia was not found to be significantly 
associated with lifetime occupational class.  However, fewer people with amblyopia 
were found to have completed higher university degrees.  This finding was supported 
by Rahi et al59 who reported upon findings of the 1958 British birth cohort with 
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respect to any association of amblyopia with diverse educational, health and social 
outcomes.  The authors could find no statistical evidence between the presence of 
amblyopia and educational attainment or paid employment.   
 
1.4.5  Emotional well-being and amblyopia 
The psychosocial impact of amblyopia and its treatment has been explored from both 
the parental and child perspective56.  Children have reported feelings of shame and 
negativity associated with amblyopia, particularly following the start of treatment.  
The initiation of therapy can draw adverse attention from others, and children have 
reported that they felt interrogated by others about their treatment (particularly if their 
treatment involved the wearing of glasses and a patch).   
 
It is important to recognise that the impact of amblyopia therapy may be experienced 
not only by the child, but also by family members54.  This could be result in impaired 
relationships between the child and parent/guardian, but also between siblings.  
Parents often state that their child may be more clingy or demanding when occlusion 
is worn; that the child’s compliance with occlusion can lead to negative behavioural 
changes; or that their child appears to be less confident when wearing their patch or 
glasses56.   
 
The issue of peer victimisation and bullying associated with amblyopia has been 
recognised55;56;58.  This may be in response to the wearing of glasses and/or occlusion 
therapy.  Horwood et al58 as part of the Avon Longitudinal Study of Parents and 
Children (ALSPAC) conducted in the UK, investigated whether wearing glasses, 
having manifest strabismus, or having a history of wearing an eye patch predisposed 
preadolescent children to being victimized more frequently at school.  In this study, 
the outcome measure used to assess whether bullying had occurred was through a 
structured face-to-face interview, conducted with the child at the age of 8.5 years.  
Children were asked if they had experienced or used any forms of overt or relational 
bullying.  The authors reported that those children who wore glasses or had a history 
of wearing an eye patch were 35% to 37% more likely to be victims of physical or 
verbal bullying (after adjustment for social class and maternal education).   
 
Williams et al55 argued the case for preschool vision screening in that those who had 
undertaken screening were likely to have concluded amblyopia therapy early (i.e. 
before school starts) and thus would avoid adverse reactions from their peers.  They 
compared two groups that had been offered preschool vision screening at the age of 
three years to those who had not; and asked the children at age 8 years whether they 
had been bullied through a standard structured interview.  The authors reported an 
almost 50% reduction in children who reported having been bullied in the group that 
had been offered preschool screening, compared to the group who had not.   
 
Not all children undertaking amblyopia therapy find the treatment a negative 
experience.  Indeed in a study by Choong et al53, the authors found no significant 
changes in parental (carer’s) stress or the child’s psychosocial well-being between an 
occluded and non-occluded group.  One factor which did result in changes in parental 
attitude towards the child was the issuing of glasses.  A statistically significant 
difference was found, where carers felt more negative towards their child once glasses 
were prescribed.  As glasses form an integral part of amblyopia therapy it could be 
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deemed that the results do in fact demonstrate psychosocial implications of amblyopia 
treatment, particularly from the carer’s perspective.   
 
Conflicting evidence exists in the adult population.  Rahi et al59 reported that adults 
with amblyopia were no more likely to be bullied (either at the age of 7 or 11 years); 
and could find no evidence for an association between the presence of amblyopia and 
participation in social activities in either childhood or adult life.  The authors also 
stated that those with amblyopia were no more likely to report depression or 
psychological distress in adult life.   
 
This finding was not supported by Packwood et al57, who explored the psychosocial 
implications of growing up and living with amblyopia in a group of adult subjects.  
The authors reported that those with amblyopia experienced more distress in several 
areas of psychological well-being, including somatisation, obsession-compulsion, 
interpersonal sensitivity, anxiety and depression.  
 
Taken in isolation, the impact of any one of the aforementioned problems may be 
minimally associated with detriment to HRQoL.  However, the cumulative effect of 
impaired reading, motor skills and psychosocial impact of amblyopia, for example, 
might influence HRQoL to a greater degree. 
 
1.4.6  The impact of strabismus upon HRQoL 
The psychosocial implications of strabismus are more accepted and recognised, 
particularly in cases of cosmetically obvious strabismus.  Detrimental implications of 
strabismus include a negative self-image, reduced self-confidence, low self-esteem 
and poor interpersonal relationships60.  The presence of a cosmetically noticeable 
strabismus has also been reported to impact upon a person’s ability to gain 
employment61;62, and in a person’s ability to attract a partner63.  The presence of 
strabismus does not only affect those in adulthood.  Uretman et al64 determined that 
children with strabismus were perceived in a negative light by adults.  The age at 
which the emergence of negative attitudes towards those with strabismus develops has 
been studied.  Paysse et al65 reported that at approximately six years of age, children 
begin to express a negative attitude towards strabismus.   
 
In adults it has been documented that those with strabismus experience more social 
anxiety and use social avoidance strategies compared to the general population66;67.  It 
could be argued therefore that surgical correction of strabismus serves to provide 
psychosocial benefits, and therefore improve HRQoL.  
 
Improvements in quality of life following strabismus surgery are well-documented in 
adults66-69, however its effect on children is not as extensively researched.  Archer et 
al70 reported upon a group of 98 children who underwent strabismus surgery 
(although it is unclear whether the purpose of surgery was purely cosmetic or 
functional in nature).  The authors stated that following surgery there were significant 
improvements in a number of quality of life dimensions, including those of anxiety, 
social relations and developmental satisfaction (parental response).    The results 
concur with those found in an adult population, and it can therefore be deemed that 
the psychosocial benefits reported in adults following strabismus surgery are also 
applicable to children. 
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1.4.7  Critique of HRQoL issues in amblyopia 
Methods of determining the impact of amblyopia and/or strabismus upon HRQoL 
differ greatly from one study to another.  Some report changes in psychosocial 
behaviour and well-being using a purpose designed questionnaire60;62;63;67;71.  Whilst 
their findings are of great clinical importance it can be difficult to compare one study 
to another due to differences in methodologies.   
 
One key component that must be considered when addressing the issue of HRQoL 
and amblyopia and/or strabismus, is that of the perspective from which the results are 
taken.  That is, are the results taken from responses from the parent; the child; or from 
and adult with a history of amblyopia and/or strabismus.  The findings of each study 
are equally valid, however it must be recognised that there may be levels of bias 
exerted depending upon which methodology is applied.  For example, studies which 
report from the parental perspective53;54;56;70 may in fact be capturing parental opinion 
regarding the condition and/or its treatment, rather than a true measure of HRQoL 
changes.     Studies that involve adults with a history of amblyopia and/or strabismus57 
are asking subjects to recall childhood experiences.  It is possible that adult 
experiences have since “tainted” the recall of such events; either exaggerating or 
diminishing the true changes in HRQoL experienced as a child.  Perhaps studies 
which report from the child perspective55;56;58 could be considered the most valid.  
They deliver insight into what is experienced at the time.  However, they are not 
without their weaknesses.  What they fail to do is inform as to whether the impact of 
amblyopia and/or strabismus (as a condition, or its treatment) is appreciated in the 
longer term, that is, into adulthood.  
 
1.4.8  The impact of the condition or the impact of treatment? 
It can be difficult to fully distinguish whether any reported detriment to HRQoL in 
amblyopia is due to the condition itself or its treatment.  This is not a factor when 
considering strabismus.  Strabismus (particularly that of large angle strabismus) is 
cosmetically noticeable and it is the impact that that has upon the person which can 
affect HRQoL.  Therefore it can be said that any study which reports upon HRQoL 
and strabismus is reporting upon the effect the condition has upon a person’s well-
being.  With amblyopia, this is not the case.  The condition itself cannot be identified 
by peers.  What is noted is the effect of treatment upon HRQoL, with the instigation 
of glasses or occlusion therapy.  Studies which report upon changes in HRQoL in 
amblyopia frequently report upon the impact of the treatment upon quality of life 
rather than the condition itself44;53-55;55-57.  Alternative studies do report upon the 
impact of amblyopia, however the measures of these studies are of adult-related issues 
(such as employment, educational attainment and risk of losing vision in the non-
amblyopic eye)9;59.  It is not possible to determine whether the same HRQoL changes 
which occur in childhood are appreciated in adulthood, because the measures used in 
the identified studies are so different.  Nonetheless it can be concluded that there is 
evidence to suggest that there are HRQoL issues related to amblyopia and/or 
strabismus and its treatment. 
 
Summary for the Clinician 
• There have been a number of studies investigating HRQoL implications of 
amblyopia and/or strabismus over recent years.  These have involved studies with 
children who have the condition, or adults who had previously undergone treatment. 
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• Studies have reported amblyopia to impact upon stereoacuity, fine motor skills and 
reading speed.   
• The presence of amblyopia does not appear to have any impact upon educational 
attainment or paid employment in adult life. 
• Amblyopia (more specifically amblyopia treatment) has been shown to impact 
negatively upon a child’s emotional well-being; and may also affect relationships 
between the child and parent/guardian. 
• The issue of bullying and amblyopia treatment requires further investigation.  
Some studies report children who had glasses or had a history of occlusion therapy 
were more likely to be victims of bullying.  However, other studies refute this. 
• Taken in isolation, the impact of any one of the aforementioned problems may be 
minimally associated with detriment to HRQoL.  However, the cumulative effect of 
impaired reading, motor skills and psychosocial impact of amblyopia, for example, 
might influence HRQoL to a greater degree. 
• The reported HRQoL implications of strabismus are related to physical appearance 
and the impact of strabismus upon self-image and interpersonal relationships.  
Surgical correction of strabismus has been reported to improve HRQoL. 
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Table 1 Summary of criteria for screening72 
Category Criteria 
Condition The condition should be an important health problem, whose 
epidemiology and natural history are understood.  There should be a 
recognisable risk factor or early symptomatic stage. 
Diagnosis There should be a simple, safe, precise and validated screening test 
which is acceptable to the population.  There should be an agreed policy 
on further investigation of individuals with a positive test result. 
Treatment There should be an effective treatment or intervention for those 
identified as having the disease or condition, with evidence of early 
treatment leading to better outcome than late treatment.  There should 
be agreed evidence-based policies which individuals should be offered 
treatment. 
Programme There should be evidence from high quality randomised controlled 
trials (RCTs) that the screening programme is effective in reducing 
mortality or morbidity.  There should be evidence that the complete 
screening programme (including the test, diagnostic procedures, and 
treatment) is clinically, socially and ethically acceptable.  The benefit of 
the programme should outweigh the physical and psychological harm.  
The cost of the programme should be economically balanced in relation 
to expenditure on medical care as a whole (i.e. value for money). 
 
Table 2  Sensitivity of cover-uncover test when specificity was set to 0.9421 
Test Amblyopia 
n=75 
(95% CI) 
Strabismus 
n=48 
(95% CI) 
Refractive 
error n=240 
(95% CI) 
Reduced VA 
n=132  
(95% CI) 
Cover-uncover 0.27  
(0.17 to 0.37) 
0.60  
(0.46 to 0.74) 
0.16  
(0.11 to 0.21) 
0.06  
(0.02 to 0.10) 
n = number of children 
 
Table 3  Sensitivity of Random Dot E and Stereo Smile by condition type*23 
Stereotest Amblyopia 
 
Reduced 
VA 
Strabismus 
 
Refractive 
error 
Specificity 
Year 1  
n=796 
n=75 n=132 n=48 n=240  
Random 
Dot E 
0.63 0.38 0.60 0.47 0.90 
Year 2 
n=1037 
n=88 n=114 n=62 n=299  
Stereo 
Smile 
0.77 0.30 0.68 0.51 0.91 
n = number of children * may have more than one condition 
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Table 4 Sensitivity of Random Dot E and Stereo Smile when specificity was set to 
0.94*21 
Test Amblyopia 
(95% CI) 
Strabismus 
(95% CI) 
Refractive 
error 
(95% CI) 
Reduced VA 
(95% CI) 
Random Dot E 0.28  
(0.18 to 0.38) 
0.29 
(0.16 to 0.42) 
0.23 
(0.18 to 0.23) 
0.24 
(0.17 to 0.31) 
Stereo Smile 0.61 
(0.51 to 0.71) 
0.58 
(0.46 to 0.70) 
0.37 
(0.32 to 0.42) 
0.20 
(0.13 to 0.27) 
* may have more than one condition 
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